Syndax Pharmaceuticals Inc (SNDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has a cash flow conversion efficiency ratio of -1.210x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.34 Million) by net assets ($41.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Syndax Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
Syndax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Syndax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Ocbc Nisp Tbk
JK:NISP
|
0.146x |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
0.055x |
|
UIE PLC
CO:UIE
|
0.044x |
|
The Baldwin Insurance Group, Inc.
NASDAQ:BWIN
|
-0.004x |
|
Australian United Investment Company Ltd
AU:AUI
|
0.021x |
|
Makalot Industrial Co Ltd
TW:1477
|
0.098x |
|
Banpu Public Company Limited
BK:BANPU
|
0.016x |
|
Fufeng Group Limited
F:FFO1
|
0.034x |
Annual Cash Flow Conversion Efficiency for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Syndax Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Syndax Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.63 Million | $-322.98 Million | -4.997x | -423.77% |
| 2024-12-31 | $288.12 Million | $-274.90 Million | -0.954x | -229.24% |
| 2023-12-31 | $554.20 Million | $-160.60 Million | -0.290x | -1.34% |
| 2022-12-31 | $467.45 Million | $-133.68 Million | -0.286x | -500.88% |
| 2021-12-31 | $408.37 Million | $29.13 Million | 0.071x | +125.25% |
| 2020-12-31 | $252.19 Million | $-71.26 Million | -0.283x | +82.36% |
| 2019-12-31 | $31.60 Million | $-50.61 Million | -1.602x | -23.98% |
| 2018-12-31 | $53.05 Million | $-68.53 Million | -1.292x | -184.50% |
| 2017-12-31 | $104.32 Million | $-47.37 Million | -0.454x | -8.68% |
| 2016-12-31 | $84.14 Million | $-35.16 Million | -0.418x | -1047.83% |
| 2015-12-31 | $66.70 Million | $-2.43 Million | -0.036x | -101.45% |
| 2014-12-31 | $-5.72 Million | $-14.39 Million | 2.518x | +508.99% |
| 2013-12-31 | $11.85 Million | $-7.29 Million | -0.616x | -294.22% |
| 2012-12-31 | $-29.29 Million | $-9.28 Million | 0.317x | -39.73% |
| 2011-12-31 | $-19.05 Million | $-10.02 Million | 0.526x | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more